Equity Overview
Price & Market Data
Price: $103.8
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $6,620,154,368
Daily Volume: 0
Performance Metrics
1 Week: 3.89%
1 Month: 12.66%
3 Months: 23.25%
6 Months: 60.03%
1 Year: 140.1%
YTD: 18.79%
Company Details
Employees: 132
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.